COMP <GO>
INSM vs UTHR // FORWARD P/E MULTIPLE
Insmed Incorporated (NASDAQ) VS. United Therapeutics Corporation (NASDAQ) • 15-METRIC TALLY: INSM 2
— UTHR 10
▲ FORWARD P/E MULTIPLE LEADER: UTHR
LAST: $112.58 (+0.89%) • MKT CAP: $24.70B
forward-pe
21.0x
LAST: $598.72 (+0.87%) • MKT CAP: $25.68B
forward-pe
17.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INSM VS. UTHR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INSM | UTHR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.70% | 87.90% | -8.20 | UTHR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.10% | -55.10 | UTHR | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 12.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.97% | 4.09% | -8.06 | UTHR | /fcf-yield <GO> |
| Operating Margin | -60.00% | 46.90% | -106.90 | UTHR | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 41.90% | -101.90 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | 66.70% | 10.60% | +56.10 | INSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.25 | 22.52 | -17.27 | UTHR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.2 | 68.6 | -6.40 | UTHR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.03 | 0.95 | +0.08 | INSM | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 21.0x | 17.8x | +3.20 | UTHR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.70B | $25.68B | -$981.7M | UTHR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INSM REV | UTHR REV | INSM GROSS % | UTHR GROSS % | INSM FCF | UTHR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $606.4M | $3.18B | 79.7% | 87.9% | -$967.6M | $1.04B |
| FY 2024 | $363.7M | $2.88B | 76.4% | 89.2% | -$705.8M | $1.08B |
| FY 2023 | $305.2M | $2.33B | — | — | -$550.0M | $873.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INSM // BETA 1.03
UTHR // BETA 0.95